Tocilizumab trade name and manufacturer information

Tocilizumab is a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor. It mainly exerts anti-inflammatory and immunomodulatory effects by blocking the IL-6 signaling pathway. The drug is jointly developed and produced by Genentech, a subsidiary of the world's leading biopharmaceutical company Roche, and Chugai Pharmaceutical, a Sino-foreign cooperation.

In the international market, the trade name of tocilizumab isActemra, while in Japan and some Asian countries and regions, it is called RoActemra. Currently, Actemra has been approved in many countries around the world for the treatment of inflammatory or immune diseases such as rheumatoid arthritis (RA), giant cell arteritis (GCA), systemic sclerosis-related interstitial lung disease (SSc-ILD), polyarticular and systemic juvenile idiopathic arthritis (PJIA and SJIA), cytokine release syndrome (CRS), and severe COVID-19.

Actemra has also been officially launched in mainland China, and was introduced and managed by Roche Pharmaceuticals (Shanghai) Co., Ltd. The drug is available in a variety of dosage forms in China, including intravenous infusion (concentrated solution for injection) and subcutaneous injection (prefilled syringe or automatic injection pen), providing flexible clinical use options. The trade name "Actemra" has long become a well-known brand of tocilizumab in the field of rheumatism and immunity, representing a new therapeutic direction targeting the IL-6 signaling pathway intervention. As the first IL-6 inhibitor approved for the treatment of cytokine release syndrome associated with CAR-T cell therapy, Actemra has become increasingly prominent in the management of complications of immunotherapy.

Globally, with the continued promotion of Roche/Genentech, the scope of indications for this drug have been continuously expanded, and dosage forms suitable for patients of different age groups have also been gradually enriched, thereby benefiting more patients with chronic inflammatory diseases. In clinical use, the manufacturer information and trade name of tocilizumab are clear, which helps doctors and patients identify the brand and source, so as to carry out long-term medication management with more peace of mind.

Reference materials:https://www.drugs.com/mtm/tocilizumab.html